Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 20.37 · gapped above the open, then crossed back over prior close. High/low 21.30 at 7:30 am ET, 20.32 at 10:00 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In December 2025, we entered into a synthetic royalty funding agreement (the "Royalty Agreement") with Royalty Pharma plc ("Royalty Pharma").”
FILING10-K0001714899-26-000021cik 0001714899
“For example, under our agreements with F-star and Genentech, the licensors control prosecution and, in the case of F-star and in specified circumstances, enforcement of certain of the patents and patent applications licensed to us.”
FILING10-K0001714899-25-000066cik 0001714899
“For example, in June 2016, we entered into a license agreement with Genentech pursuant to which we received an exclusive license to certain of Genentech's intellectual property relating to our LRRK2 program, including our BIIB122/DNL151 product candidate.”
FILING10-K0001714899-25-000066cik 0001714899
“Our existing commitments primarily relate to our obligations under existing lease agreements, and certain clinical and manufacturing agreements, including the DMSA with Lonza Sales AG ("Lonza") for the development and manufacture of biologic products.”
FILING10-K0001714899-25-000066cik 0001714899
“We currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.”
FILING10-K0001714899-25-000066cik 0001714899
“We currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.”
FILING10-K0001714899-25-000066cik 0001714899
“We currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.”
FILING10-K0001714899-25-000066cik 0001714899
“Takeda paid us a $40.0 million upfront payment related to the collaboration, and an additional $110.0 million under a share purchase agreement in February 2018.”
FILING10-K0001714899-25-000066cik 0001714899
“LRRK2 Program Manufacturing Biogen will be responsible for delivering all supplies for clinical trials and commercial production for LRRK2 Products, except that we will deliver such supplies until the point of transition which will be mutually agreed by us and Biogen, but in no event later than commencement of activities to support commercial launch, and in any event we retain manufacturing rights for certain independent clinical activities.”
FILING10-K0001714899-25-000066cik 0001714899
“Sanofi will be responsible for delivering all supplies for current and future clinical trials and commercial production for Peripheral Products.”
FILING10-K0001714899-25-000066cik 0001714899
“In addition, we are required to make contingent payments, to F-star Ltd and the former shareholders of F-star Gamma, up to a maximum amount following completion of the research phase of the F-star collaboration of $243.0 million in the aggregate upon the achievement of certain defined preclinical, clinical, regulatory and commercial milestones.”
FILING10-K0001714899-25-000066cik 0001714899
“In December 2025, we entered into a synthetic royalty funding agreement with Royalty Pharma plc ("Royalty Pharma"), pursuant to which Royalty Pharma has agreed to provide us with up to $275.0 million in funding in exchange for a 9.25% royalty on future worldwide net sales of tividenofusp alfa, which will cease upon reaching a multiple of 3.0x, or 2.5x if achieved by the first quarter of 2039.”
FILING10-K0001714899-26-000021cik 0001714899
“In connection with our collaboration with Biogen, we also entered into a common stock purchase agreement pursuant to which we sold 13,310,243 shares of our common stock to BIMA for an aggregate purchase price of $465.0 million .”
FILING10-K0001714899-25-000066cik 0001714899
Watchlist prices, news filtered to it, and its next report on your desk.
Denali Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Denali Therapeutics Inc. has 7 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Denali Therapeutics Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
DNLI (Denali Therapeutics Inc.) has 7 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.